

Review Article

Challenges in the Development of Dengue Vaccine

Abstract

The development of a dengue vaccine presents numerous challenges, largely due to the complexity of the virus and the human immune response. One of the primary hurdles is Antibody-Dependent Enhancement (ADE), where antibodies from a previous dengue infection can facilitate a more severe secondary infection with a different serotype, exacerbating the disease. Cross-reactivity with other flaviviruses, such as Zika, complicates the immune response further. Additionally, the vaccine must elicit a balanced immune response against all four dengue serotypes, which is difficult to achieve. The role of T follicular helper (T_{FH}) cells in enhancing vaccine efficacy has emerged as a critical area of focus. Efficiently targeting and inducing T_{FH} cells through specific adjuvants could enhance neutralizing antibody production and long-lasting immunity, addressing some of the current vaccine limitations. Despite these challenges, ongoing research and trials continue to advance the field towards a more effective dengue vaccine.

Key words: Dengue vaccine development, Antibody Dependent Enhancement (ADE), Cross reactivity, T follicular helper (T_{FH}) cells, Dengue serotypes, vaccine efficacy.

INTRODUCTION

Dengue is an increasing public health threat

Dengue poses a growing threat globally with all four virus types (DENV-1 to 4) circulating in endemic areas [1]. Population growth, expanding Aedes mosquito habitats, and travel have fueled rising DENV infections [2]. Globally, over 390 million infections occur annually, with more than 95 million being clinically apparent [3]. Supportive care, administered by experienced practitioners, effectively manages DENV without a specific therapeutic.

DENV infections can vary from asymptomatic to severe, causing mild illnesses or classic dengue fever. Severe cases of dengue can cause plasma leakage, bleeding, shock, and death, especially with multiple DENV infections [4-7]. Dengue is caused by four antigenically different DENV types (DENV-1 to -4). Protection after one infection can be complex for vaccine development due to immune

response variations [8]. Various factors interact to either protect against or enhance disease, including viral characteristics, host immunity, genetics, epidemiological context, and their timing [9]. To combat the issue, vaccine developers aim for tetravalent immunity against all DENV types, hindered by incomplete understanding of key immune responses.

Dengue vaccine development landscape

Developing a successful dengue vaccine has been a challenge for 75 years, needed for global prevention and control [10].

Sanofi Pasteur's Dengvaxia® is the only licensed dengue vaccine available in 20 endemic countries, including the EU and US. Implementation is limited to Brazil and the Philippines due to concerns about severe dengue risk in vaccinated individuals [11].

Two other dengue vaccines in phase 3 trials: Takeda's TAK-003 in multi-country trial and Instituto Butantan's Butantan-DV in Brazil. TAK-003 uses DENV-2 backbone with chimeras, while Butantan-

DV is an attenuated live virus vaccine with a DENV chimera. Safety and efficacy reports are expected.

PATHOGENESIS OF DENGUE

The four dengue virus serotypes (DENV1-4) are closely related and share 65–70% nucleotide sequence identity[12]. A primary infection is the first instance of a certain serotype's infection. Although they can occasionally result in hemorrhagic fever in certain individuals, particularly in newborns delivered to mothers who are immune to DENV, the majority of primary infections are often asymptomatic or present as a moderate fever. Secondary dengue infection is the term for a subsequent infection with a distinct serotype that can cause serious clinical symptoms like dengue shock syndrome (DSS) or dengue hemorrhagic fever (DHF)[13–15].

A person is resistant to contracting the same serotype again after having previously been infected with it. But because the heterologous immunity is transient, infection with a different serotype may subsequently arise. Numerous cohort studies indicate that the heterotypic protective immunity gradually diminishes over the course of the next year or two[16].

Numerous viral and host factors, including the non-structural protein 1 (NS1) viral antigen, DENV genome variation, sub-genomic RNA, memory cross-reactive T cells, anti-DENV NS1 antibodies, and autoimmunity, have been linked to the pathogenesis of dengue. The combined effect of all the aforementioned elements is primarily responsible for the severe dengue symptoms in people.

Complex interplay of viral and host factors in pathogenesis of dengue virus infection : Dengue virus infection involves viral and host factors leading to immune

dysfunction, inflammation, and vascular damage.

- Viral factors: NS1 disruption, antibody enhancement
- Host factors: T-cell dysfunction, complement activation
- Immune response: Inflammatory cytokine release, endothelial dysfunction

1. DENV NS1 disrupts TLR-4, leading to activation of macrophages and PBMCs, as well as complement activation, contributing to the pathogenesis of dengue virus infection.
2. DENV Genome variations, including sRNA, contribute to an increase in viral virulence and enhance viral replication, leading to more severe infections.
3. Antibody dependent enhancement through Fc γ receptor mediated amplification in viral replication suppresses the type-1 IFN response and increases IL-10 levels, exacerbating the immune response.
4. Host factors such as anti-NS1 antibodies can lead to autoimmune disorders and endothelial cell autophagy, further complicating the immune response against dengue virus infection.
5. T-cells play a complex role in dengue virus infection, with cross-reactive T-cell activation, T-cell apoptosis, and defective Treg cells contributing to a detrimental immune response and impaired immune suppression.
6. Complement activation, membrane attack complex formation, and inflammatory cytokine release (IFN- γ , IL-2, TNF- α , MCP-1, IL-6, IL-8) lead to endothelial cell dysfunction, plasma leakage,

coagulopathy, and thrombocytopenia in dengue virus infection.

7. The interplay between viral factors and host factors in dengue virus infection results in a complex immune response, highlighting the importance of understanding the intricate mechanisms involved in the pathogenesis of the disease [17-19].

DENGUE VACCINE TYPES

Various dengue vaccinations have been developed and assessed.

Live-attenuated vaccine

DF protection can be obtained with a live attenuated dengue vaccine. With the attenuated or weakened version of DENV included in these vaccinations, an immune response can be triggered without serious disease [20]. Up to date there are two licensed live-attenuated dengue vaccines are available:

Dengvaxia (CYD-TDV) and Dengvaxia tetravalent (Dengvaxia TV)

Approved for use in individuals between the ages of 9 and 45 who reside in dengue-endemic areas and have a history of illness.

Dengvaxia© (CYD-TDV)

Dengvaxia, also known as CYD-TDV, is the first approved live tetravalent dengue attenuated vaccine candidate. It employs the yellow fever vaccine strain 17D (YF17D) as a basis by substituting sections from four DENV serotypes for the YF17D premembrane (prM) and envelope (E) regions. It offers protection against every DENV serotype. It produces cross-reactive and serotype-specific T cell responses against DENV structural antigens, which raises the possibility of

antibody-dependent enhancement (ADE).

The WHO advises against giving this vaccination to anybody who is not seropositive, highlighting the importance of screening or ruling out prior infection in every case before administering the vaccine to mitigate the risk of ADE. Based on efficacy tests done over 30,000 children in ten dengue-endemic Asian and Latin American countries, the vaccine was originally licensed in December 2015. Phase 3 studies have shown the advantages of vaccination at the population level, regardless of age, serostatus, or serotype, although the concern remains about the potential for ADE with tetravalent vaccines.[21].

Tetravax (TV003/TV005)

Tetravax (TV003/TV005) differs greatly from CYD-TDV in terms of features including viral particle structure, immunogenicity, and infectivity. DENV virulence was decreased by nucleotide deletion of 30 untranslated regions and structural gene prM/E chimerization. Comparing CYD to TV003/TV005, CYD showed lesser resistance to DENV type 2, a weaker adaptive immune response, and a greater risk of viremia.

TAK-003

Phase II trials are being conducted on TAK 003, a live attenuated chimeric tetravalent dengue vaccine (also known as DENVax). DENV serotype-dependent protective effect was demonstrated by TAK 003. DENV2 neutralizing antibody levels were greater in TAK 003 but DENV3 and DENV4 protection levels were lower. As a result, its safety profile is not fully known [22].

TDEN F17/F19 vaccine

An alternative to the live-attenuated dengue vaccine is TDEN F17/F19

vaccine. It is a safe, well-tolerated immunogenic DENV vaccine candidate, as shown by the Phase II research. One month following the second dosage, antibody responses to all four forms of DENV were shown in more than half of the babies, toddlers, and kids [23].

Dengue virus DNA vaccine

A vaccine containing nucleic acids has been created and is presently undergoing Phase 1 clinical testing.

D1ME100

The monovalent DNA plasmid vaccine D1ME100 contains the prM and E genes of the DENV 1 virus and is presently undergoing Phase I clinical studies.

Tetravalent dengue DNA vaccine

Equivalent quantities of plasmid DNA inoculum expressing dengue 1, 2, 3, and 4 prM and E genes cloned in VR1012 were combined to develop the tetravalent dengue DNA vaccine [24].

Inactivated vaccine

DENV that has been inactivated or killed is used in inactivated vaccinations. They can trigger an immunological response but cannot itself cause illness. Usually, inactivated vaccinations are administered in multiple doses.

TDEV PIV

As part of a Phase I research trial, Walter Reed Army Research Institute and GlaxoSmithKline developed this quadrivalent DENV purified inactivated vaccine [25].

Subunit vaccine

Subunit vaccines include certain immunogenic DENV proteins or components that might elicit an immune response. Certain proteins, like as non-structural proteins and envelope proteins (E), can be targeted by these vaccines. Subunit vaccinations may call for several doses.

V180 (DEN-80E)

DEN 80E, also known as V180, is a highly promising vaccine candidate that has successfully completed Phase I clinical studies. It is a possible quadrivalent vaccine.

Viral-vectored vaccine

They introduce DENV genes and proteins into the body by the use of other safe viruses, such as chimera or adenoviruses. These viral vectors trigger an anti-DENV immune response.

It is important to remember that country-to-country variations may exist in the dengue vaccine's accessibility and recommended dosage. Guidelines for the administration of dengue vaccinations and their incorporation into dengue preventive and control tactics are provided by the World Health Organization (WHO)[26].



Fig 1. Current dengue vaccines

PRECLINICAL EVALUATION

Dengvaxia®

Developed initially by the NIH, the University of St. Louis, and Acambis Inc., and later licensed by Sanofi Pasteur, Dengvaxia® utilizes the ChimeriVax™ technology. This approach involves using a yellow fever virus (YFV) vaccine strain where the pre-membrane (prM) and envelope (E) genes of YFV are replaced with corresponding genes from all four dengue virus (DENV) serotypes. [27,28] Preclinical evaluations demonstrated that the tetravalent ChimeriVax™ DENV 1-4 vaccine exhibited reduced neurovirulence in mice and *Macaca fascicularis* monkeys compared to the parental YFV strain.[29] The vaccine also generated strong neutralizing antibody responses and provided significant protection against wild-type DENV challenges in vaccinated cynomolgus macaques.[30]

TV003/TV005

The TV003/TV005 dengue vaccines, developed by the National Institute of Allergy and Infectious Diseases (NIAID) starting in 1996, use live attenuated DENV strains. The initial attenuation strategy involved deleting 30 nucleotides from the 3' untranslated region (UTR) of DENV-4.[30] This method was extended to other serotypes to create a tetravalent vaccine.

Preclinical studies in rhesus macaques showed that these vaccine candidates induced strong neutralizing antibody responses and provided protection against wild-type DENV challenges.[31] Various attenuated chimeric viruses, combining genetic elements from different serotypes, were evaluated to enhance the vaccine's safety and efficacy, showing promising results in animal models.

TAK-003 (DENVax)

TAK-003, developed from the DENV-2 16681 strain isolated in Thailand, involves serial passages in primary dog kidney cells to achieve attenuation.[32-34] This strain was then used to create chimeric viruses for DENV-1, DENV-3, and DENV-4 by replacing their prM and E genes.[35] The resulting tetravalent vaccine formulations exhibited reduced neurovirulence and induced high neutralizing antibody titers in AG129 knockout mice.[35] Preclinical evaluation in cynomolgus macaques showed that TAK-003 was well tolerated and provided robust protection against all four DENV serotypes after two immunizations, supporting its potential as a safe and effective dengue vaccine.[36]

CLINICAL EVALUATION

Dengvaxia

Phase I and II trials of Dengvaxia® demonstrated its safety and

immunogenicity in adults and children, showing mild to moderate side effects and inducing specific T-helper responses without significant severe adverse events.[37,38] Phase III trials in children revealed age-dependent efficacy, higher in those older than 9 years, but a concerning risk of severe dengue in younger, dengue-naïve children [39]. The vaccine showed varied efficacy across DENV serotypes, with DENV-3 and DENV-4 being more effectively targeted than DENV-1 and DENV-2 [40]. Despite high overall efficacy, post-vaccination models predicted substantial hospitalizations, emphasizing the need for ongoing phase IV surveillance.

TV003/TV005

Clinical trials of TV003 and TV005, developed at NIAID, indicated good safety and balanced neutralizing antibody responses in flavivirus-naïve subjects, with TV005 showing improved efficacy against DENV-2 [31]. A single dose of these vaccines induced significant neutralizing antibody responses against all DENV serotypes. The Butantan Institute licensed TV003 as Butantan-DV, and phase II trials in Brazil demonstrated robust and balanced immune responses in both DENV-naïve and exposed adults [41]. A large phase III trial is ongoing to further assess its safety and efficacy across different age groups.

TAK-003 (DENVax)

TAK-003, developed by Takeda, showed promising safety and immunogenicity in early trials, with a reformulation improving responses against DENV-4 [42]. Phase II trials in DENV-exposed individuals highlighted robust neutralizing antibody responses, though lower for DENV-4 [43]. A phase III trial in children from dengue-endemic regions revealed

high efficacy against DENV-2, with lower but notable efficacy against other serotypes [44]. The vaccine maintained similar efficacy in seronegative and seropositive individuals. Long-term data at three years post-vaccination indicated overall reduced efficacy, stressing the need for extended phase IV trials to assess long-term protection and potential waning immunity [45].

CHALLENGES IN DENGUE VACCINE DEVELOPMENT

Antibody Dependent Enhancement (ADE)

Dengue fever is a self-limiting febrile disease caused by DENVs in the majority of clinically evident cases. Severe dengue, on the other hand, is only rarely caused by DENV infections. This kind of dengue sickness has the potential to be lethal and is characterized by increased capillary permeability that can cause shock and plasma leakage[46]. Sequential infection with several serotypes of DENVs has been linked to severe dengue. According to several theories, antibodies produced against a particular DENV serotype after an initial infection bind to that serotype but do not neutralize a different DENV serotype that is encountered during a later infection. Actually, through their Fc γ receptors, the cross-reacting or neutralizing antibodies at insufficient levels promote enhanced absorption of the non-neutralized DENV into monocytes and macrophages, which are thought to be the in vivo sites of DENV reproduction. This phenomenon is termed antibody-dependent enhancement[47].

Both pathogenic and protective antibodies are produced by spontaneous DENV infections. The pathogenic antibodies are basically disease-spreading (DENV ADE promoting) antibodies because they allow non-neutralized and immature DENV to

enter monocytes and macrophages. Studies have shown that prM and the FL epitope (FLE) induce cross-reactive, disease-spreading antibodies and are highly immunodominant. About 60% of the human antibody response is directed against the prM protein, according to an investigation of memory B cell responses in DENV-infected people. The prM of all four DENV serotypes may be recognized by these highly cross-reactive antibodies. Moreover, anti-prM antibodies strongly stimulate ADE but are ineffective in neutralizing DENV infectivity[48].

The challenges posed by entire DENV-based vaccination approaches force us to redirect our emphasis to the dengue vaccine candidates that have been developed and are primarily able to elicit type-specific immune responses. The ADE phenomenon, which is primarily linked to prM and FLE antibodies, may be avoided if the developed vaccines primarily generated EDIII-directed serotype specific antibodies in the absence of prM and FLE antibodies. By producing type-specific antibodies against each of the four DENV serotypes, the vaccines potentially circumvent the virus's ability to evade the immune system[49].

Three scenarios of dengue virus infection:

A. Without dengue antibodies, the virus causes a mild infection as it interacts with DC-SIGN receptors on macrophages.

B. High affinity dengue antibodies effectively neutralize the virus, preventing infection.

C. Low affinity dengue antibodies lead to increased viremia and antibody-dependent enhancement (ADE), worsening the infection due to ineffective neutralization and enhanced viral entry through FC receptors on macrophages [49]

Cross Reactivity with Other Flaviviruses

The chance of developing severe dengue and dengue with warning signals in the future is increased by prior DENV infection. There is a possibility of cross-reaction between non-neutralizing antibodies produced against the envelope E protein during the initial DENV infection and additional heterologous Flaviviruses or DENV serotypes. Due to antibody-dependent enhancement (ADE), these DENV cross-reactive antibodies may make it easier for myeloid cells to become infected with the virus later on in secondary or tertiary heterologous infections. This might worsen dengue fever in patients. Comparably, peptides shared by DENV serotypes and other Flaviviruses can alter the responses of CD (CD4⁺ and CD8⁺) T cells to a heterologous Flavivirus infection. Studies using mice and in vitro challenges have demonstrated that DENV-specific antibodies can amplify ZIKV infection [50].

Targeting T_{FH} Cells To Enhance Dengue Vaccine Efficacy

Antigens can be classified into T cell dependent and T cell independent based on their requirement for T cell help in eliciting an immune response. T cell dependent antigens require the assistance of T helper cells to stimulate B cells for antibody production. These antigens typically include proteins that are processed and presented by antigen-presenting cells (APCs) to T helper cells, which then provide the necessary signals for B cell activation and differentiation. In contrast, T cell independent antigens can directly stimulate B cells without T cell help. These antigens are often polysaccharides or repeating epitopes that can cross-link B cell receptors (BCRs) and induce an antibody response.

The "Hapten-Carrier" effect illustrates the mechanism of T cell dependent antigen activation. A hapten is a small molecule

that, by itself, is not immunogenic but can become immunogenic when conjugated to a larger carrier protein. The carrier protein is processed and presented by APCs to T helper cells, which then help activate B cells specific to the hapten, leading to a robust immune response.

Specialized $CD4^+$ T cells called T follicular helper cells (T_{FH} cells) aid in the establishment of germinal centers (GCs) and have a n impact on B-cell responses. T_{FH} cells appear to significantly expand in acute dengue, which associated with clinical disease severity and plasmablast expansion. This increase in frequency also correlated with DENV-specific IgG, Neut50 titres and with NS1-specific antibody titres. [51] Numerous studies have demonstrated a direct link between boosting T_{FH} cells in connection to vaccinations and effectively inducing memory B cells and plasma cells that will generate particular neutralizing antibodies against influenza and Ebola. Future vaccine design will benefit from knowing

which possible adjuvants can effectively target and trigger a T_{FH} response. Adjuvants are necessary for most vaccines in order to boost neutralizing antibody titers, create long-lasting immunity, and minimize the number of doses needed. Adjuvants containing water in oil, such as ISA-51, Montanide ISA 720, and incomplete Freund's adjuvant (IFA), have been demonstrated to specifically enhance the T_{FH} response when used in the setting of T_{FH} induction. According to a different study, the MF59 oil-in-water adjuvant directly stimulates GC responses by mediating a strong T_{FH} response. Since TLR agonists can all increase T_{FH} cells, other adjuvants including TLR4, TLR6, TLR7, TLR8, and TLR9 agonists have all shown a great deal of interest in the usage of vaccination adjuvants. To overcome the seronegative group setback in dengue vaccination, the T_{FH} cells must be potently and selectively increased. This can be achieved by utilizing a potent adjuvant like ADA to develop specificity to all four serotypes simultaneously.[52]




Fig 2. Enhancement of dengue vaccine by targeting T_{FH} cells to overcome dengue serostatus effect: (A) Administering dengue vaccine to naive dengue individual with T_{FH} Adjuvant (ADA) (B) Administering dengue vaccine to naive individuals without T_{FH} adjuvant (ADA). [53]

Need for Screening

A pre-vaccination screening technique, in which only those who test positive for dengue are vaccinated, is the recommended approach for nations contemplating CYD-TDV vaccination as part of their dengue control program, according to the World Health Organization (WHO) [11]. CYD-TDV was authorized by the US Food and Drug Administration (FDA) in May 2019 for use in seropositive individuals aged 9 to 16

who reside in endemic areas of the country. The use of this vaccination in seropositive persons across a broader age range has also been approved by the European Medicines Agency. Therefore, serostatus screening must be completed before to vaccination in order to use CYD-TDV programmatically. The "test and vaccinate" approach, also known as pre-vaccination screening, can be carried out with IgG-based enzyme-linked immunosorbent assays (ELISAs) or rapid

diagnostic tests (RDTs). In order to maximize community level benefit and reduce risk, a screening test should ideally be extremely sensitive and specific, minimizing false positives and negatives and accurately screening for seropositive individuals only. It should also be inexpensive, easy to use, and yield results quickly[54].

Economic Evaluations of Dengue Vaccination

Under certain circumstances, dengue vaccination is seen to be among the most economical measures to stop the spread of dengue disease in many nations. However, since there are currently relatively few research on its economic evaluation and the vaccine's actual use, additional scientific proof of its possible advantages is still needed. A modelling approach was used in economic evaluation studies carried out in multiple countries to forecast the economic impact of vaccination by taking into account multiple possible scenarios. However, before the dengue vaccine is really introduced in each individual nation, modelling studies on the vaccine's cost-effectiveness seem to be essential.[55][56]

The dengue vaccine is still not part of many nations' current immunization programs, despite the fact that it has the potential to lessen the burden of dengue disease, particularly in areas with moderate and high endemicity[57]. In order to help policy makers make more precise decisions when allocating resources and budget, a comprehensive economic evaluation study should be conducted. This is because the government or insurance companies require it as a factor in the decision-making process. In certain countries, like those in Southeast Asia, the government may heavily subsidize dengue vaccination, which could

have an impact on healthcare policies[58]. The study's dengue vaccine CEA results showed that the vaccination is a potentially cost-effective intervention that might be developed and made available in all areas[59].

CONCLUSION

In conclusion, dengue remains a significant global health threat, exacerbated by population growth, expanded mosquito habitats, and increased travel. The disease's complexity is evident in the variation of its clinical manifestations and the intricacies involved in vaccine development. Despite the introduction of Sanofi Pasteur's Dengvaxia® and promising advancements with TAK-003 and Butantan-DV, the challenge of achieving effective, broad-based immunity persists. Antibody-dependent enhancement (ADE) and cross-reactivity with other flaviviruses further complicate vaccine efficacy. Targeting T follicular helper (T_{FH}) cells has emerged as a potential strategy to enhance vaccine responses. Continued research and innovation are essential to overcome these obstacles and develop a universally effective dengue vaccine.

REFERENCES

1. Gubler DJ. Dengue, urbanization and globalization: The Unholy Trinity of the 21(st) century. *Trop Med Health*. 2011;39(4 Suppl):3–11.
2. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. *Nat Rev Dis Primers*. 2016;2:16055. doi: 10.1038/nrdp.2016.55. PMID: 27534439.

3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GRW, Simmons CP, Scott TW, Farrar JJ, Hay SI. The global distribution and burden of dengue. *Nature*. 2013 Apr 25;496(7446):504-7. doi: 10.1038/nature12060. PMID: 23563266.
4. Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, Thaisomboonsuk B, Nisalak A, Weg A, Ellison D, Macareo L, Yoon IK, Jarman R, Thomas S, Rothman AL, Endy T, Cauchemez S. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. *Nature*. 2018 May 31;557(7707):719-23. DOI: 10.1038/s41586-018-0157-4. PMID: 29795354.
5. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. *Proc Natl Acad Sci U S A*. 2016 Jan 19;113(3):728-33. doi: 10.1073/pnas.1522136113. PMID: 26729879.
6. Anderson KB, Gibbons RV, Cummings DAT, Nisalak A, Green S, Libraty DH, Jarman RG, Srikiatkachorn A, Mammen MP, Darunee B, Yoon IK, Endy TP. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. *J Infect Dis*. 2014 Feb 1;209(3):360-8. DOI: 10.1093/infdis/jit436. PMID: 23964110.
7. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, Kuan G, Gordon A, Balmaseda A, Harris E. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. *PLoS Negl Trop Dis*. 2013 Aug 22;7(8):e2357. DOI: 10.1371/journal.pntd.0002357. PMID: 23951377.
8. Halstead SB. Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. *Yale J Biol Med*. 1970;42:350-62.
9. Guzman MG, Harris E. Dengue. *Lancet*. 2015 Jan 31;385(9966):453-65. doi: 10.1016/S0140-6736(14)60572-9. PMID: 25230594.
10. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. *Science*. 1945 Mar 23;101(2634):640-2. doi: 10.1126/science.101.2634.640. PMID: 17844088.
11. Dengue vaccine: WHO position paper, September 2018 - Recommendations. *Vaccine*. 2018. doi:10.1016/j.vaccine.2018.09.063 PMID: 30424888.
12. Weaver SC, Vasilakis N. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. *Infect Genet Evol*. 2009 Jul;9(4):523-540.
13. Mathew A, Rothman AL. Understanding the contribution of cellular immunity to dengue

- disease pathogenesis. *Immunol Rev.* 2008 Aug;225:300-313.
14. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. *Arch Virol.* 2013 Jul;158(7):1445-1459.
 15. Simmons CP. Dengue. In: Cohen J, Opal SM, Powderly WG, editors. *Infectious diseases.* 3rd ed. London: Elsevier; 2010. Chapter 127, p. 1253-1256. Available from: <https://www.sciencedirect.com/science/article/pii/B9780323045797001271> [cited 2020 Aug 29].
 16. Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, Jarman RG, Srikiatkachorn A, Mammen MP, Darunee B, Yoon IK, Endy TP. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. *J Infect Dis.* 2014 Feb 1;209(3):360-8. doi: 10.1093/infdis/jit436.
 17. Nimmannitya S, Halstead SB, Cohen SN, Margiotta MR. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. I. Observations on hospitalized patients with hemorrhagic fever. *Am J Trop Med Hyg.* 1969 Nov;18(6):954-971.
 18. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. *Yale J Biol Med.* 1970 Oct;42(5):311-328.
 19. Halstead S. Recent advances in understanding dengue. 2019. F1000Research [Internet]. [cited 2020 Jan 4];8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676504/>
 20. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. *Arch Med Res.* 2002;33:330-342.
 21. Ng DH, Wong JG, Thein TL, Leo YS, Lye DC. The significance of prolonged and saddleback fever in hospitalised adult dengue. *PLoS One* 2016;11:e0167025.
 22. Nguyen Tien T, Probandari A, Ahmad RA. Barriers to engaging communities in a dengue vector control program: An implementation research in an urban area in Hanoi city, Vietnam. *Am J Trop Med Hyg.* 2019;100:964-973.
 23. Wharton-Smith A, Green J, Loh EC, Gorrie A, Syed Omar SF, Bacchus L, Lum LCS. Using clinical practice guidelines to manage dengue: A qualitative study in a Malaysian hospital. *BMC Infect Dis.* 2019;19:45.
 24. Kellstein D, Fernandes L. Symptomatic treatment of dengue: Should the NSAID contraindication be reconsidered? *Postgrad Med.* 2019;131:109-116.
 25. World Health Organization. *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition.* Geneva: World Health Organization; 2009.
 26. Flores HA, Taneja de Bruyne J, O'Donnell TB, Nhu VT, Giang NT, Xuan Trang HT, Thuy Van HT, Long VT, Dui LT, Huy HLA, Duyen HTL, Van Thuy NT, Phong NT, Vinh Chau NV, Hue Kien DT,

- Thuy Vi T, Wills B, O'Neill SL, Simmons CP, Carrington LB. Multiple Wolbachia strains provide comparative levels of protection against dengue virus infection in *Aedes aegypti*. *PLoS Pathog.* 2020;16:e1008433.
27. Gruenberg A, Woo WS, Biedrzycka A, Wright PJ. Partial nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue virus type 2, New Guinea C and PUO-218 strains. *J Gen Virol.* 1988;69:1391-1398. doi: 10.1099/0022-1317-69-2-325
28. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. *J Virol.* 2000;74:5477-5485. doi: 10.1128/JVI.74.12.5477-5485.2000.
29. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T. Safety and efficacy of chimeric yellow fever dengue virus tetravalent vaccine formulations in nonhuman primates. *J Virol.* 2004;78(9):4761-4775. doi: 10.1128/jvi.78.9.4761-4775.2004.
30. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. *J Virol.* 1996;70:3930-3937. doi: 10.1128/JVI.70.6.3930-3937.1996.
31. Whitehead SS, Falgout B, Hanley KA, Blaney JE, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. *J Virol.* 2003;77:1653-1657. doi: 10.1128/JVI.77.2.1653-1657.2003.
32. Yoksan S, Bhamarapavati N, Halstead S. Dengue virus vaccine development: study on biological markers of cloned dengue 1-4 viruses serially passaged in primary kidney cells. In: St. George TD, Kay BH, Blok J, editors. *Arbovirus research in Australia, Proceedings of the fourth symposium.* Brisbane: CSIRO/QIMR; 1986. p. 35-38.
33. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapavati N, Gubler DJ. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. *Virology.* 1997;230:300-308. doi: 10.1006/viro.1997.8500.
34. Butrapet S, Huang CY, Pierro DJ, Bhamarapavati N, Gubler DJ, Kinney RM. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. *J Virol.* 2000;74:3011-3019. doi: 10.1128/jvi.74.7.3011-3019.2000.
35. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapavati N, Gubler DJ,

- Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. *J Virol.* 2003;77:11436-11447. doi: 10.1128/jvi.77.21.11436-11447.2003.
36. Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M, Powell TD, Livengood JA, Kinney RM, Huang CY, Stinchcomb DT. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques. *Am J Trop Med Hyg.* 2011;84(6):978-987. doi: 10.4269/ajtmh.2011.10-0592.
37. Tricou V, Sáez-Llorens X, Yu D, Rivera L, Jimeno J, Villarreal AC, Dato E, Saldaña de Suman O, Montenegro N, DeAntonio R, Mazara S, Vargas M, Mendoza D, Rauscher M, Brose M, Lefevre I, Tuboi S, Borkowski A, Wallace D. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial. *Lancet.* 2020;395(10234):1434-1443. doi: 10.1016/S0140-6736(20)30556-0.
38. van Der Most RG, Murali-Krishna K, Ahmed R, Strauss JH. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. *J Virol.* 2000;74(17):8094-8101. doi: 10.1128/jvi.74.17.8094-8101.2000.
39. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Ismail HHH, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenoghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. *N Engl J Med.* 2015;373:1195-1206. doi: 10.1056/NEJMoa1506223.
40. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenoghe A, Viviani S, Tornieporth NG, Lang J. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. *Lancet.* 2012;380:1559-1567. [https://doi.org/10.1016/S0140-6736\(12\)61428-7](https://doi.org/10.1016/S0140-6736(12)61428-7).
41. Kallas EG, Precioso AR, Palacios R, Thomé B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Salomão MG, da Silva A, Espinola HM, Santos JdP, Santos CLS, Timenetsky MCST, Miraglia JL, Gallina NMF, Weiskopf D, Sette A, Goulart R, Salles RT, Maestri A, Sallum AME, Farhat SCL, Sakita NK, Ferreira JCOA, Silveira CGT, Costa PR, Raw I, Whitehead SS, Durbin AP, Kalil J. Safety and immunogenicity of the tetravalent, live attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. *Lancet Infect Dis.* 2020;20(7):839-850. [https://doi.org/10.1016/S1473-3099\(20\)30023-2](https://doi.org/10.1016/S1473-3099(20)30023-2).

42. Rupp R, Luckasen GJ, Kirstein JL, Osorio JE, Santangelo JD, Raanan M, Smith MK, Wallace D, Gordon GS, Stinchcomb DT. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a Phase 1b randomized study. *Vaccine*. 2015;33(46):6351-6359. <https://doi.org/10.1016/j.vaccine.2015.09.008>.
43. Sáez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, Borkowski A, Wallace D. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. *Lancet Infect Dis*. 2017;17(6):615-625. [https://doi.org/10.1016/S1473-3099\(17\)30166-4](https://doi.org/10.1016/S1473-3099(17)30166-4).
44. Biswal S, Reynales H, Sáez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F, Fernando L, Dietze R, Luz K, Venâncio da Cunha R, Jimeno J, López-Medina E, Borkowski A, Brose M, Rauscher M, LeFevre I, Bizjajeva S, Bravo L, Wallace D; TIDES Study Group. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. *N Engl J Med*. 2019;381:2009-2019. <https://doi.org/10.1056/NEJMoa1903869>.
45. Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, Bravo L, Sirivichayakul C, Kosalaraksa P, Martinez Vargas L, Yu D, Watanaveeradej V, Espinoza F, Dietze R, Fernando L, Wickramasinghe P, Moreira Jr ED, Fernando AD, Gunasekera D, Luz K, Venâncio da Cunha R, Rauscher M, Zent O, Liu M, Hoffman E, LeFevre I, Tricou V, Wallace D, Alera MT, Borkowski A. Three years efficacy and safety of Takeda's dengue vaccine candidate (TAK 003). *Clin Infect Dis*. 2021. <https://doi.org/10.1093/cid/ciab86>.
46. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. *N Engl J Med*. 2012;366:1423-1432. doi: 10.1056/NEJMra1110265.
47. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes: I. Infection enhancement by non-neutralizing antibody. *J Exp Med*. 1977;146:201-217. doi: 10.1084/jem.146.1.201
48. Dejnirattisai W, Jumnainsong A, Onsirirakul N, Fitton P, Vasana-wathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Srean G. Cross-reacting antibodies enhance dengue virus infection in humans. *Science*. 2010;328:745-748. doi: 10.1126/science.1185181
49. Shukla R, Ramasamy V, Shanmugam RK, Ahuja R, Khanna N. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. *Front Cell Infect Microbiol*. 2020;10:572681. doi: 10.3389/fcimb.2020.572681
50. Salgado BB, Maués FCJ, Jordão M, Pereira RL, Toledo-Teixeira DA, Parise PL, Granja F, Souza HFS, Yamamoto MM, Chiang JO, Martins LC, Boscardin SB,

- Lalwani JDB, Vasconcelos PFC, Proença-Modena JL, Lalwani P. Antibody cross-reactivity and evidence of susceptibility to emerging Flaviviruses in the dengue-endemic Brazilian Amazon. *Int J Infect Dis.* 2023;129:142-151. <https://doi.org/10.1016/j.ijid.2023.01.033>
51. Wijesinghe A, Gamage J, Goonewardena H, Gomes L, Jayathilaka D, Wijeratne DT, de Alwis R, Jeewandara C, Wijewickrama A, Ogg GS, Malavige GN. Phenotype and functionality of follicular helper T cells in patients with acute dengue infection. *J Biomed Sci.* 2020;27:50. <https://doi.org/10.1186/s12929-020-00641-2>.
52. Izmirly AM, Pelletier A-N, Connors J, Taramangalam B, Alturki SO, Gordon EA, Alturki SO, Mell JC, Swaminathan G, Karthik V, Kutzler MA, Kallas EG, Sekaly R-P, Haddad EK. Pre-vaccination frequency of circulatory T_{FH} is associated with robust immune response to TV003 dengue vaccine. *PLoS Pathog.* 2022;18(1):e1009903. <https://doi.org/10.1371/journal.ppat.1009903>.
53. Izmirly AM, Alturki SO, Alturki SO, Connors J, Haddad EK. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. *Front. Immunol.* 2020;11:1055. <https://doi.org/10.3389/fimmu.2020.01055>.
54. Hunsperger E, Peeling R, Gubler DJ, Ooi EE. Dengue pre-vaccination serology screening for the use of Dengvaxia®. *J Travel Med.* 2019;26. doi: 10.1093/jtm/taz092.
55. Halstead SB. Dengue vaccine development: a 75% solution? *Lancet.* 2012;380(9853):153-156. doi: 10.1016/S01406736(12)61510-4.
56. Siqueira J, Martelli C, Coelho GE, Simplicio A, Hatch DL. Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. *Emerg Infect Dis.* 2005;11(1):48-53. doi: 10.3201/eid1101.031091
57. Flasche S, Jit M, Rodríguez-Barraquer I, Coudeville L, Recker M, Koelle K, Milne G, Hladish TJ, Perkins TA, Cummings DA, Dorigatti I, Laydon DJ, España G, Kelso J, Longini IM, Lourenco J, Pearson CAB, Reiner RC, Mier-Y-Terán-Romero L, Vannice K, Ferguson NM. The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study. *PLoS Med.* 2016;13(11). doi: 10.1371/journal.pmed.1002181.
58. Endo IC, Ziegelmann PK, Patel P. The economic promise of developing and implementing dengue vaccines: evidence from a systematic review. *Vaccine.* 2016;34(50):6133-6147. doi: 10.1016/j.vaccine.2016.10.037
59. Recker M, Vannice KS, Hombach J, Jit M, Simmons CP. Assessing dengue vaccination impact: model challenges and future directions. *Vaccine.* 2016;34(38):4461-4465. doi: 10.1016/j.vaccine.2016.06.082

UNDER PEER REVIEW